Ritu Baral
Stock Analyst
(n/a)
# 1,607
Out of 4,648 analysts
34
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $44.82 | +74.03% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $269.95 | +37.43% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $68.09 | +43.93% | 3 | Aug 9, 2024 | |
| SPRO Spero Therapeutics | Upgrades: Buy | n/a | $1.29 | - | 3 | Aug 6, 2024 | |
| SAGE Sage Therapeutics | Downgrades: Hold | $16 → $10 | $5.81 | +72.12% | 5 | Jul 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $331.32 | +17.71% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $5.42 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $123.07 | +42.20% | 1 | Mar 22, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $32 → $21 | $14.62 | +43.64% | 1 | Aug 8, 2022 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | n/a | $1.08 | - | 1 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.54 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.02 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.00 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.08 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $45.17 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.10 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.49 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.35 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $431.57 | - | 2 | Jan 12, 2018 |
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $44.82
Upside: +74.03%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $269.95
Upside: +37.43%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $68.09
Upside: +43.93%
Spero Therapeutics
Aug 6, 2024
Upgrades: Buy
Price Target: n/a
Current: $1.29
Upside: -
Sage Therapeutics
Jul 30, 2024
Downgrades: Hold
Price Target: $16 → $10
Current: $5.81
Upside: +72.12%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $331.32
Upside: +17.71%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.42
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $123.07
Upside: +42.20%
ACADIA Pharmaceuticals
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $14.62
Upside: +43.64%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.08
Upside: -
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.54
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.02
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.00
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.08
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $45.17
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.10
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $14.49
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.35
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $431.57
Upside: -